How can process control strategies and release/shelf‑life specifications be appropriately established when CMC timelines are compressed and early data come from limited clinical batches?

In what ways can Quality‑by‑Design (QbD) principles be applied to gene therapy CMC development to reduce long‑term lifecycle management burden?

Beyond the typical CQAs (genome titer, total particle number, infectivity, potency, aggregation, and particle composition), are there additional attributes that should be characterised for gene therapy products?

How should analytical methods for CQA testing be upgraded or expanded throughout product lifecycle management, given evolving platforms and limited industry standardisation?

What real‑world experiences demonstrate how automation improves consistency, reduces variability, and strengthens compliance in gene therapy manufacturing?

What examples exist of data modelling, AI, or digital‑twin technologies being applied to gene therapy manufacturing processes?